首個商業化產品希維奧®未來2-3年預計將達成多個里程碑事件
格隆匯12月20日|德琪醫藥-B(6996.HK)中國血液腫瘤事業部負責人於立新表示,希維奧®在中國大陸市場獲批上市標誌着德琪醫藥向商業化階段邁向了新台階,也使得中國大陸成為繼美國、以色列、歐盟和韓國之後,全球第5、亞太第2個批准這款核輸出蛋白(XPO1)抑制劑創新藥物的地區。
未來預計2022年上半年將會在澳大利亞、新加坡、中國香港獲批,2022年年中將在中國台灣獲批。預計2022年下半年將進入澳大利亞全民健康保險,2023年進入韓國全民健康保險,2024年進入中國醫保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.